Fig. 2: Direct targeting and establishment of enhancers at the CD276 locus by PAX3-FOXO1 and MYOD1, and heterogenous expression of FGFR4 and CD276 on RMS cell lines, CDXs or PDXs. | Nature Communications

Fig. 2: Direct targeting and establishment of enhancers at the CD276 locus by PAX3-FOXO1 and MYOD1, and heterogenous expression of FGFR4 and CD276 on RMS cell lines, CDXs or PDXs.

From: CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma

Fig. 2

A H3K27ac (top), MYOD1 (middle), and PAX3-FOXO1 (bottom) ChIP-seq at the CD276 locus in FP-RMS cell lines (red, dark blue, and purple, respectively) and FN-RMS cell lines (orange, green). B Scatterplot of FGFR4 and CD276 mRNA demonstrated a generally high level of expression for CD276 but more variable expression of FGFR4 in RMS tumors or cells compared to normal tissues. C–F Flow cytometry was used to measure FGFR4 or CD276 expression on patient-derived RMS cell lines (C) or patient-derived xenografts (PDX, E) by staining with anti-human FGFR4 antibody (3A11) and anti-human CD276 antibody (MGA271). Co-staining of FGFR4 and CD276 showed heterogeneity of expression of both targets on RMS cells and PDXs. Cell line or PDX IDs and tumor types are listed in the right tables (C and E). Quantification of FGFR4 or CD276 molecules on each RMS cell and CDX (D) or PDXs (F) was performed using a phycoerythrin (PE) fluorescence quantitation kit. Dots with error bars representing mean ± SD in Figure D show protein expression measured by flow cytometric analysis from 3 independent experiments. Source data is provided as a Source Data file.

Back to article page